Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Ther
ClinicalTrials.gov study NCT07071337. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine
ClinicalTrials.gov study NCT04968964. IPD Sharing: NO. Countries: 1. Publications: 0.
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
ClinicalTrials.gov study NCT06635447. IPD Sharing: YES. Countries: 1. Publications: 0.
Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors
ClinicalTrials.gov study NCT07258108. IPD Sharing: NO. Countries: 1. Publications: 0.
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
ClinicalTrials.gov study NCT06556862. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Assessment of Bone Micro-Architecture Using HR-pQCT
ClinicalTrials.gov study NCT01367730. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06650748. IPD Sharing: NO. Countries: 1. Publications: 0.
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
ClinicalTrials.gov study NCT05025735. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
ClinicalTrials.gov study NCT05399329. IPD Sharing: NO. Countries: 1. Publications: 0.
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
ClinicalTrials.gov study NCT05186545. IPD Sharing: Not stated. Countries: 1. Publications: 0.
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers
ClinicalTrials.gov study NCT05986071. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
ClinicalTrials.gov study NCT04651920. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
ClinicalTrials.gov study NCT04666805. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06914440. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT04282031. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
ClinicalTrials.gov study NCT04033172. IPD Sharing: NO. Countries: 1. Publications: 0.
To Evaluate 24-hr Glucose After OD vs BD AZD1656
ClinicalTrials.gov study NCT00819884. IPD Sharing: Not stated. Countries: 1. Publications: 0.
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
ClinicalTrials.gov study NCT05594095. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT07162051. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
ClinicalTrials.gov study NCT04862663. IPD Sharing: YES. Countries: 23. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.